NCT04083196View on ClinicalTrials.gov

A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2019

Primary Completion Date

October 13, 2021

Study Completion Date

October 13, 2021

Conditions

HPV InfectionHPV-Related Cervical Carcinoma

Interventions

BIOLOGICAL

11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle

BIOLOGICAL

Placebo

Trial Locations (1)

Unknown

Liuzhou Center for Disease Control and Prevention, Liuzhou

All Listed Sponsors

collaborator

Chengdu Institute of Biological Products Co.,Ltd.

INDUSTRY

collaborator

Simoon Record Pharma Information Consulting Co., Ltd.

INDUSTRY

collaborator

Guangxi Center for Disease Control and Prevention

OTHER_GOV

collaborator

Beijing Kantorico Statistical Technology Co., Ltd.

UNKNOWN

lead

National Vaccine and Serum Institute, China

INDUSTRY

NCT04083196 - A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years | Biotech Hunter | Biotech Hunter